/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at.
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Table: IMU-838 Shows Acceleration of Time to Clinical Improvement
High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population:
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients
[6], as compared to placebo (FAS).
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS).